Best Peptides for Muscle Growth & Recovery (2026) - Evidence, Dosing, Cost & Supplier Comparison

BPC-157 (Body Protection Compound-157) is a 15-amino-acid gastric pentadecapeptide with the broadest preclinical evidence base of any tissue repair peptide. A 2025 systematic review in HSS Journal identified 36 studies (35 preclinical, 1 clinical) showing that BPC-157 enhances growth hormone receptor expression, activates angiogenesis pathways such as VEGFR2 and the Akt-eNOS axis, and reduces inflammatory cytokines.

Why it matters for muscle: BPC-157 does not directly build muscle mass. It accelerates healing of muscle tears, tendon strains, and connective-tissue injuries that limit training capacity. In rat models, BPC-157 reversed corticosteroid-impaired muscle healing and restored full functional recovery. A small retrospective human study found that 7 of 12 patients with chronic knee pain reported relief lasting longer than 6 months after a single intra-articular injection.

Key limitation: nearly all data is preclinical. No large randomized controlled trials in humans have been completed. The FDA has not approved BPC-157 for any indication, and WADA prohibits it at all times.

TB-500 is a synthetic fragment (Ac-LKKTETQ) of Thymosin Beta-4, a 43-amino-acid protein that regulates actin dynamics, cell migration, and angiogenesis. Where BPC-157 excels at local injury repair, TB-500 provides broader vascular and tissue-regeneration support.

Why it matters for muscle: TB-500 supports the vascular infrastructure that muscle tissue needs to heal. In cardiac injury models, TB-500 reduced infarct size and promoted cardiomyocyte survival. In connective-tissue models, it accelerated tendon and ligament repair with improved collagen-fiber organization. For athletes, that translates to broader recovery support around the injury site and surrounding connective tissue matrix.

Key limitation: most evidence is preclinical. TB-500 is not FDA-approved, remains WADA-prohibited, and its reconstituted stability is shorter than most peptides at roughly 1 to 2 weeks.

CJC-1295 is a synthetic GHRH analog that stimulates the pituitary to release growth hormone in a sustained, dose-dependent manner. In a 2006 human trial, single subcutaneous injections increased mean plasma GH concentrations 2-fold to 10-fold for more than 6 days and increased IGF-1 1.5-fold to 3-fold for 9 to 11 days. Ipamorelin is a selective ghrelin receptor agonist that induces clean GH pulses without elevating cortisol or prolactin.

Why they are paired: CJC-1295 provides sustained background GH elevation while Ipamorelin delivers acute GH pulses. Together, they aim for a more physiologic GH pattern than either compound alone and remain the most discussed GH-secretagogue pairing in the grey-market peptide space.

Key limitation: while GH and IGF-1 increases are well documented in humans, no clinical trial shows that the combination produces measurable lean-mass gains in healthy resistance-training individuals. Neither compound is FDA-approved, and both are WADA-prohibited.

IGF-1 LR3 (Long Arg3 Insulin-Like Growth Factor-1) is a synthetic IGF-1 analog with a 13-amino-acid N-terminal extension and an arginine substitution at position 3. Those modifications reduce binding to IGF-binding proteins and extend its half-life from minutes to roughly 20 to 30 hours.

Why it matters for muscle: IGF-1 LR3 bypasses the GH axis entirely and directly activates IGF-1 receptors on muscle cells. That triggers the PI3K/Akt/mTOR pathway for protein synthesis and the MAPK pathway for cell proliferation while also activating satellite cells involved in muscle-fiber repair and formation.

Key limitation: the same anabolic potency that makes IGF-1 LR3 attractive also creates risk. Hypoglycemia is the primary acute concern, and sustained IGF-1 elevation raises theoretical concerns about unwanted cell growth. It is not FDA-approved and is prohibited by WADA.

MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA Type-c) is a mitochondria-derived peptide that activates AMPK, the master metabolic regulator. Unlike the other peptides in this guide, it does not directly target muscle protein synthesis. It instead improves cellular energy handling and glucose metabolism.

Why it matters for muscle: MOTS-c addresses the metabolic substrate layer of performance. By activating AMPK and improving glucose uptake independently of insulin, it may create a more efficient energy environment for training and recovery. That benefit is indirect, but relevant for athletes whose bottleneck is training capacity rather than direct hypertrophy signaling.

Key limitation: MOTS-c is still in the earliest stage of human investigation. Muscle-specific benefits are extrapolated from metabolic pathway data rather than direct hypertrophy trials, and supplier availability is narrower than for the main repair compounds.

GHK-Cu (Glycyl-Histidyl-Lysine Copper) is a naturally occurring tripeptide that declines significantly with age. Computational analysis suggests it modulates more than 4,000 human genes involved in tissue remodeling, collagen synthesis, antioxidant defense, and anti-inflammatory signaling.

Why it matters for muscle: GHK-Cu supports the connective-tissue matrix around muscle fibers, including fascia, tendons, and extracellular matrix. By promoting collagen synthesis, reducing NF-kB-mediated inflammation, and stimulating fibroblast activity, it can improve the structural environment for repair.

Key limitation: its effects on muscle are indirect, and copper-cycling awareness is required because prolonged uninterrupted use may increase copper accumulation risk. It is not FDA-approved for muscle growth, and WADA status should be checked against the current list.